SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST...
September 30 2020 - 9:26AM
- Sorrento to initiate testing with a selection of its agents in
combination with ViralClear’s anti-viral compound for possible
synergistic anti-viral effect against SARS-CoV-2 in the preclinical
model of Golden Syrian hamster.
- ViralClear to contribute its oral antiviral merimepodib (IMPDH
inhibitor) which is currently in a Phase 2 trial in combination
with remdesivir to treat COVID-19.
- Sorrento to initially make available STI-1400 neutralizing
antibody candidate for testing.
ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM)
and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”)
announced the companies are exploring the synergistic potential of
small molecules and antibodies combination therapies against
COVID-19.
In general, multi-modal approaches are
considered the most likely to succeed anti-viral strategies. Even
with highly effective stand-alone therapies, a synergistic
combination can be pursued to help reduce the effective dose needed
of each individual agent and aim to ensure maximum effect.
The agreement between ViralClear Pharmaceuticals, Inc. (Parent
company BioSig Technologies, Inc. Nasdaq: BSGM), and Sorrento
Therapeutics will allow for testing of merimepodib with
neutralizing antibodies in the Golden Syrian hamster model of
COVID-19.
The study will look for synergy at the effective doses between
the two drugs already in human clinical trials and will try to
specifically demonstrate that the combined benefits in
strengthening and accelerating viral clearance exceed what each
drug could deliver by itself.
Pending the outcome of these studies, the results might be
presented to the FDA to support the initiation of a human clinical
trial of the drug combination.
About ViralClear Pharmaceuticals and
Merimepodib BioSig’s Technologies, Inc (Nasdaq:
BSGM www.biosig.com) subsidiary, ViralClear Pharmaceuticals,
Inc. (ViralClear), is seeking to develop a novel pharmaceutical
called merimepodib to treat patients with COVID-19. Merimepodib is
intended to be orally administered, and has demonstrated
broad-spectrum in vitro antiviral activity, including strong
activity against SARS-CoV-2 in cell cultures. Merimepodib was
previously in development as a treatment for chronic hepatitis C
and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with
12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400
subjects and patients and an extensive preclinical safety package
was completed. A manuscript titled, “The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
Remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro”, was submitted to an online peer-reviewed life sciences
journal. This manuscript is authored by Natalya Bukreyeva, Rachel
A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and
Slobodan Paessler of the UTMB Galveston National Laboratory and Dr.
Jerome Zeldis of ViralClear as a corresponding author. This article
highlights pre-clinical data generated under contract with
Galveston National Laboratory at The University of Texas Medical
Branch. About Sorrento Therapeutics,
Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to treat
cancers. Sorrento's multimodal, multipronged approach to fighting
cancer is made possible by its extensive immuno-oncology platforms,
including key assets such as fully human antibodies ("G-MAB™
library"), clinical stage immuno-cellular therapies ("CAR-T",
"DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage
oncolytic virus ("Seprehvir®", “Seprehvec™”). Sorrento is also
developing potential antiviral therapies and vaccines against
coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™,
COVI-GUARD™, COVI-SHIELD™ and T-VIVA-19™; and diagnostic test
solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine
topical system) 1.8% for the treatment of post-herpetic neuralgia.
RTX has completed a phase 1B trial for intractable pain associated
with cancer and a phase 1B trial in osteoarthritis patients.
ZTlido® was approved by the FDA on February 28, 2018.
For more information, visit
www.sorrentotherapeutics.com
Forward-looking Statements This
press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024